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S U M M A R Y
The Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with life-threatening
severe illnesses and a mortality rate of approximately 35%, particularly in patients with underlying
comorbidities. A systematic analysis of 637 MERS-CoV cases suggests that diabetes and hypertension are
equally prevalent in approximately 50% of the patients. Cardiac diseases are present in 30% and obesity in
16% of the cases. These conditions down-regulate the synthesis of proinﬂammatory cytokines and impair
the host’s innate and humoral immune systems. In conclusion, protection against MERS-CoV and other
respiratory infections can be improved if public health vaccination strategies are tailored to target
persons with chronic disorders.
Crown Copyright  2016 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Since September 2012, the World Health Organization (WHO)
has been notiﬁed of 1626 laboratory-conﬁrmed cases of Middle
East respiratory syndrome coronavirus (MERS-CoV) infection from
26 countries, with 586 related deaths. Reported cases have mainly
been from countries in the Middle East, but a number of European
and East Asian countries have reported individuals who had
travelled to the Middle East.1
MERS-CoV is a zoonotic virus that can lead to secondary human
infections. Dromedary camels have been identiﬁed as the
intermediate host, with closely related virus sequences in bats.
Although community-wide transmission has not been observed,
human-to-human transmission has been noted in households and
in the health care setting.2–5 Additional cases are expected to arise
in the Middle East and continue to spread to other countries
through travelers who may acquire the infection in that region.
MERS-CoV infects more males than females1,3,6,7 and is
accompanied by a cluster of ﬂu-like symptoms8–10 and life-
threatening severe illnesses including acute respiratory distress* Corresponding author.
E-mail address: alaa.badawi@phac-aspc.gc.ca (A. Badawi).
http://dx.doi.org/10.1016/j.ijid.2016.06.015
1201-9712/Crown Copyright  2016 Published by Elsevier Ltd on behalf of International 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).syndrome, pneumonia, myocarditis, and organ failure.3–7 Death
occurs in 30%1 to 60%7 of the cases, with an overall average of
approximately 35% according to estimates from the WHO notiﬁed
cases. It is believed that subjects particularly vulnerable to severe
disease are those with pre-existing medical conditions such as
diabetes, cardiovascular diseases, renal failure, obesity, and
immunodeﬁciency.7,9 Evaluating the prevalence of these chronic
conditions is fundamental to mitigate MERS-CoV complications.
However, this effort has been hindered by the limited number of
cases in some studies, the varying study designs, and the narrow
regional spread of the disease.4–6,9
The present study was undertaken to provide a systematic
evaluation and detailed estimate of the prevalence of comorbid-
ities in severe MERS-CoV cases. This assessment may aid the public
health sector while developing policies for surveillance, prepared-
ness, and response to MERS-CoV and its severe outcomes.
2. Methods
2.1. Search strategy and selection criteria
A search was conducted in PubMed, Ovid MEDLINE, EMBASE,
and EMBASE Classic databases to the last week of January
2016 using the search terms (MeSH) ‘‘Middle East respiratorySociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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sion, Cardiovascular diseases’’ OR ‘‘Obesity’’. The search was
limited to English language articles describing the epidemiological,
demographic, and clinical features of MERS-CoV cases and
reporting the prevalence of a number of chronic diseases in
infected adults (age >19 years). Reports published as review
articles, letters, case studies, editorials, conference abstracts,
vaccination trials, family-based studies, and articles without
abstracts were excluded.
The search identiﬁed 36 records; an additional six reports were
identiﬁed from a search of the bibliographies of previously
obtained articles and other sources such as Google, Google Scholar,
and the AMED (Allied and Complementary Medicine) search
engine, for a total of 42 records. Following screening for duplicate
records, the 42 records were all retained for abstract scanning
against the above-mentioned inclusion/exclusion criteria. The
abstracts of the identiﬁed studies were reviewed independently by
both authors. Differences were resolved through discussion, until a
consensus was reached. The abstract review resulted in the
exclusion of 28 records. Full-text retrieval and review were
conducted for the remaining 14 articles. Two studies were then
eliminated based upon the above selection criteria (Figure 1). TheFigure 1. Systematic literature review process. The ﬂow diagram describes the systempercentage agreement on the inclusion between the two reviewers
was 86%, with Cohen’s kappa statistic k = 0.72 (95% conﬁdence
interval (95% CI) 0.58–0.85). A total of 12 peer-reviewed articles
were selected for the present study (Table 1).1–12
2.2. Data extraction and analysis
The prevalence of comorbidities including diabetes, hyper-
tension, cardiovascular disease (CVD)/coronary artery disease
(CAD), and obesity (Figure 1), together with clinical symptoms
such as cough, fever, shortness of breath, and sore throat, were
extracted from the identiﬁed studies (Table 1). The primary
outcome measure was the prevalence of comorbidities in severe
MERS-CoV cases. Meta-analysis of proportions (and 95% CI) was
calculated for the clinical symptoms and for each of the selected
comorbidities using OpenMeta Analyst version 10.10 (www.
cebm.brown.edu/open_meta), a free, cross-platform, open-
source program. A binary random-effects model was used,
since it was assumed that the relationship between the
comorbidities and severe MERS-CoV varies across populations.
The presence of heterogeneity among the identiﬁed studies
(Cochran’s Q) and the extent of heterogeneity (I2 index) wereatic review of the literature for the proportion of comorbidities in MERS-CoV.
Table 1
Characteristics of the identiﬁed studies and meta-analysis of the clinical symptoms in MERS-CoV
Study [Ref.]a Dates (mm.yy) Number Age (years) Symptoms (%)
All M F Cough Fever Shortness of breath Sore throat
Assiri et al., 2016 [2] 09.14–01.15 38 28 10 51 77 92 58
Alraddadi et al., 2016 [11] 03.12–09.14 30 29 1 49
Noorwali et al., 2015 [8] 03.14–06.14 261 171 90 45.6 65 63 52 37
Shalhoub et al., 2015 [10] 04.14–06.14 24 14 10 66 88 79 83
Al-Tawﬁq et al., 2014a [9] 04.14–06.14 17 11 6 62 86 40 67 7
Al-Tawﬁq et al., 2014b [12] 04.14–06.14 5 3 2 57.6
Arabi et al., 2014 [6] 12.12–08.13 12 8 4 59 83 67 92 8
Memish et al., 2014 [5] 06.13–08.13 12 6 6 36 100 100 100 80
Assiri et al., 2013a [7] 09.12–06.13 47 36 11 64.5 83 87 72 21
Assiri et al., 2013b [3] 04.13–05.13 23 17 6 56 87 87 48
Memish et al., 2013 [4] 7 0 7 43 29 57 57
WHO, 2013 [1] 09.12–10.13 161 104 57 50
Total/overall 09.12–01.15 637 427 210 53  3b
(36–66)c
Prevalence  SEd 80  5 77  6 68  8 39  11
95% CI 70–89 66–89 53–84 17–61
Qe 45.2 63.2 67.6 103.4
I2 (%) 82.3 87.3 89.6 95.2
MERS-CoV, Middle East respiratory syndrome coronavirus; mm, month; yy, year; M, male; F, female; WHO, World Health Organization; SE, standard error; CI, conﬁdence
interval; KSA, Kingdom of Saudi Arabia.
a All studies were from KSA, except WHO 2013 [1], which examined samples pooled from France, Germany, Italy, Jordan, KSA, Qatar, Tunisia, UAE, and the UK.
b Average  SE.
c Age range.
d Meta-analysis for the prevalence was calculated from binary random-effects model analysis.
e p < 0.001.
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illustrate the prevalence of comorbidities in severe MERS-CoV
from the selected studies and to inspect the heterogeneity of the
individual ﬁndings.
3. Results
Systematic analysis of the studies describing the epidemiologi-
cal, demographic, and clinical features of MERS-CoV cases and
reporting the prevalence of a number of chronic diseases in the
infectious disease identiﬁed 12 reports1–12 with 637 patients
(Table 1), representing approximately 40% of the WHO conﬁrmed
cases. The majority of the cases were from the Middle East,
particularly Saudi Arabia; a few came from France, Germany, Italy,
Jordan, Tunisia, and the UK.1 The number of cases in the selected
studies varied by approximately 52-fold and ranged from 512 to
2618 cases. The sex ratio (male to female) was 2.03 and the overall
average age ( standard error (SE)) of the subjects was 53  3 years
(range 36–66 years).
Meta-analysis of the identiﬁed studies showed that the most
prevalent clinical symptoms were cough (80  5%, 95% CI 70–89%)
and fever (77  6%, 95% CI 66–89%), followed by shortness of breath
(68  8%, 95% CI 53–84%) and sore throat (39  11%, 95% CI 17–61%).
There was signiﬁcant heterogeneity (Cochran’s Q) in the estimates of
clinical symptoms among the examined studies (p < 0.001) with an I2
index varying from 82.3% to 95.2% (Table 1). As shown in Figure 2
(inserts a and b), diabetes and hypertension were equally prevalent,
in 51  8% (95% CI 36–66%) and 48  9% (95% CI 31–65%) of the
patients, respectively. Cardiac diseases were present in 31  5% (95%
CI 20–41%) and obesity in 16  2% (95% CI 12–19%) (Figure 2, inserts c
and d). The proportions of diabetes, hypertension, CAD/CVD, and
obesity varied by 8-, 2.8-, 9.3-, and 3.1-fold, respectively, among the
identiﬁed studies. This wide among-studies variation in the propor-
tion of comorbidities may have resulted in the signiﬁcant heteroge-
neity (Cochran’s Q) observed for estimates of diabetes, hypertension,
and cardiac diseases (p < 0.001), but not obesity with an I2 index
ranging from 84.5–94.1% (Figure 2).4. Discussion
The emergence of MERS-CoV was to a great extent contained
within the Arabian Peninsula.1 The male predominance in the
culture of this region and other Middle Eastern countries may have
been reﬂected in the 2-fold higher number of males than females
observed in the 637 cases examined. However, both sexes
exhibited clinical presentations similar in symptomatology and
frequency to those noted in other severe acute respiratory
infections (SARI), e.g., inﬂuenza A H1N1.14 These generally include
fever, new onset or exacerbation of cough, breathing difﬁculty, and
sore throat (Table 1). Severe illnesses may subsequently manifest
as pneumonia, acute respiratory distress syndrome, encephalitis,
myocarditis, or other severe and life-threatening complications.3,7
Meta-analysis of the data extracted from the studies identiﬁed
(Figure 2) suggests that diabetes and hypertension are equally
prevalent in approximately 50% of the patients. Cardiac diseases
(CVD/CAD) and obesity were present in 30% and 16% of the cases,
respectively. The increased risk of developing severe MERS-CoV
complications in people with underlying chronic diseases was
similarly noted for inﬂuenza and inﬂuenza-related complications.
A recent study noted that, compared to subjects with no
comorbidities, severe pandemic inﬂuenza occurred signiﬁcantly
more often in those who were obese (odds ratio (OR) for mortality
2.74, 95% CI 1.56–4.80) and in those who had cardiovascular
disease (OR 2.92, 95% CI 1.76–4.86), hypertension (OR 1.49, 95% CI
1.10–2.01) and neuromuscular disease (OR 2.68, 95% CI 1.91–
3.75).15 The chronic conditions inﬂuencing the severity of MERS-
CoV such as diabetes, hypertension, obesity, and CAD/CVD, have
also been noted to have similar effects in other respiratory illnesses
such as inﬂuenza15 and inﬂuenza A H1N1.16–18 In contrast, the
prevalence of comorbidities such as immunodeﬁciency and HIV
have been reported to be low in severe MERS-CoV cases (range
0–5%)1,3 compared, for example, to their rates in severe inﬂuenza A
H1N1 cases (range 3–32%).16,19
Metabolic syndrome-related conditions such as diabetes,
hypertension, CAD/CVD, and obesity, together with their predis-
posing conditions, can be linked etiologically to the pathogenesis
Figure 2. Meta-analysis of the proportion of comorbidities in MERS-CoV cases. Weights were calculated from binary random-effects model analysis. Values represent
proportions of diabetes (a), hypertension (b), coronary artery disease/cardiovascular disease (CAD/CVD) (c), and obesity (d) in severe MERS-CoV cases and the 95% conﬁdence
intervals. Inserts within each panel show the total number of subjects analyzed (n) and prevalence (SE) of the comorbidity (%), together with the heterogeneity analysis carried
out using the Q test and the among-studies variation (I2 index).
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mediators of the host innate immune response to pathogenesis. For
example, diabetes, hyperglycemia, and insulinopenia attenuate the
synthesis of proinﬂammatory cytokines such as interferon gamma
(IFN-g) and interleukins (ILs) and their downstream acute phase
reactants, to functionally impair the innate and humoral immune
systems of the host.20 Chronic diseases share several common
features with infectious disorders and their complications, such as
endothelial dysfunction, the proinﬂammatory state, and the
attenuation of the innate immune response.21–23 The cytokine
overload related to the Th1 to Th2 shift in severe viral infection
when accompanied by the cytokine synthesis that arises from
metabolic diseases, can be detrimental to the endothelium and
lead to a range of subsequent complications.22 The potential role of
altered innate immunity and the shift in the Th1 (microbicidal
action of IFN-g) to Th2 (anti-inﬂammatory IL-4, -5, -10, and -13)
response in linking metabolic diseases to severe viral presentation,
may also be supported by the high prevalence of allergy observed
in fatal viral infections24 and the eosinophilic responses in other
infections.25 Furthermore, metabolic disorders impair macrophage
and lymphocyte functions with a subsequent status of reduced
immune response,26 which may render individuals more suscep-
tible to infectious disease complications. In support, levels of
glycated hemoglobin (HbA1c) 9%, for example, have been linked
to a 60% increased risk of pneumonia-related severity and
hospitalization.27 Furthermore, the OR for severe MERS-CoV has
been reported to range from 7.2 to 15.7 in diabetic subjects.2,9–11
However, this causality cannot be simply substantiated from
the observed elevated proportions of chronic disorders in MERS-
CoV. It could be a mere reﬂection of the high prevalence of non-
communicable diseases recognized in the Middle East region.
Previous studies have reported diabetes prevalence of up to34.9% among the countries of the Arabian Peninsula, with higher
rates in men.28 The prevalence of metabolic disorders such as
impaired glucose tolerance (IGT, a pre-diabetic status) in this
region has been estimated at 7.8%.29 Although some of the chronic
disease trends in this region are largely consistent with global
patterns, some conditions are more prominent causes of prema-
ture death and disability than they are worldwide, e.g., CVD and
depression.30 These observations may imply that the high
frequency of chronic diseases in severe MERS-CoV simply reﬂects
their elevated prevalence in the Middle East region.
The present study has several limitations. The reports identiﬁed
showed a wide among-studies variance in the proportion of
diabetes, hypertension, CAD/CVD, and obesity (Figure 2), which
may have contributed to the observed signiﬁcant heterogeneity.
Additional sources of heterogeneity may relate to the large
variation among studies in the sample size (5 to 261 patients)
and the different study designs. These factors may levy some
limitations on the estimated contribution of chronic diseases to
severe MERS-CoV cases and render the results as a guide to
generate more accurate estimates for national or international
intervention strategies for infectious diseases in subjects with
chronic disorders. Further investigations are warranted to examine
the nature and extent of coexistence between MERS-CoV severity
and non-communicable diseases.
If causality exists between chronic diseases and MERS-CoV,
targeted vaccination strategies against this (and other) respiratory
infection(s) could be considered for vulnerable sub-populations as
an effective public health intervention approach. Public health
practices to prevent MERS-CoV and its related complications could
be suggested to emulate those proposed previously for seasonal
inﬂuenza. During the 1957–58 pandemic and in response to
substantial morbidity and mortality, the US Surgeon General
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chronic debilitating disease, people aged 65 years, and pregnant
women.31 For these high-risk groups, the ﬁrst recommendation for
national universal seasonal inﬂuenza vaccination was established
in 2010 by the Advisory Committee on Immunization Practices
(ACIP).32 A recent systematic review demonstrated that inﬂuenza
vaccination can prevent all-cause hospitalization in infected
subjects.33 For example, in diabetic patients and people aged
65 years, vaccination prevented all-cause hospitalization with a
vaccine effectiveness of 58% and 45%, respectively.33 Furthermore,
a signiﬁcant protective effect of inﬂuenza vaccine was noted on
intensive care unit admission (vaccine effectiveness of 81%), all-
cause mortality (32%), cardiac death (16%), and hospitalization due
to pneumonia (14%).34 However, given the quality of the body of
evidence, it was proposed that these observations should be
considered with caution.33,34 Indeed, despite numerous recom-
mendations from public health organizations across the world (US
Centers for Disease Control and Prevention (CDC), WHO, etc.) to
administer respiratory disease vaccines annually (e.g., inﬂuenza),
the vaccination rates in subjects with chronic diseases remains
low. The current level of vaccination falls short of the 2010 health
objectives call in elderly (90%) and younger (60%) individuals with
co-existing risk factors (e.g., diabetes).
The prevalence of chronic diseases in middle- and low-income
countries is rising as their populations age and lifestyle and dietary
habits change. To improve the protection against MERS-CoV and
other respiratory infections in persons with chronic disorders, the
introduction of a targeted public health vaccination intervention
strategy is essential.
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